Encourages Member States to adopt, where appropriate, regulatory frameworks to control the production, distribution and commercialization of pharmaceutical preparations containing ephedrine and pseudoephedrine, to prevent diversion, including through the sending of pre-export notifications, without impairing the availability of essential pharmaceutical preparations for medical use;